Compile Data Set for Download or QSAR
Report error Found 38 Enz. Inhib. hit(s) with all data for entry = 10499
TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541748(US11267815, Example 1)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541749(US11267815, Example 2)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541748(US11267815, Example 1)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541750(US11267815, Example 3)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541749(US11267815, Example 2)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541751(US11267815, Example 4)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541750(US11267815, Example 3)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541752(US11267815, Example 5)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541751(US11267815, Example 4)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541753(US11267815, Example 6)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541752(US11267815, Example 5)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541754(US11267815, Example 7)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541753(US11267815, Example 6)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541763(US11267815, Example 16)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541764(US11267815, Example 17)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541765(US11267815, Example 18)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541766(US11267815, Example 19)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541755(US11267815, Example 8)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541754(US11267815, Example 7)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541756(US11267815, Example 9)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541755(US11267815, Example 8)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541757(US11267815, Example 10)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541756(US11267815, Example 9)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541758(US11267815, Example 11)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541757(US11267815, Example 10)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541759(US11267815, Example 12)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541758(US11267815, Example 11)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541760(US11267815, Example 13)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541759(US11267815, Example 12)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541761(US11267815, Example 14)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541760(US11267815, Example 13)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541762(US11267815, Example 15)
Affinity DataIC50: 20nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541762(US11267815, Example 15)
Affinity DataIC50: 110nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541761(US11267815, Example 14)
Affinity DataIC50: 110nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541763(US11267815, Example 16)
Affinity DataIC50: 200nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541764(US11267815, Example 17)
Affinity DataIC50: 200nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541765(US11267815, Example 18)
Affinity DataIC50: 200nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 4(Human)
Shanghai Ringene Biopharma

US Patent
LigandPNGBDBM541766(US11267815, Example 19)
Affinity DataIC50: 200nMAssay Description:(1) Preparation of 1×Kinase buffer; (2) Preparation of the gradient concentrations of the compounds: the concentration of the compounds to be tested ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent